Today's Focus

Borui Pharmaceuticals: subsidiary polypeptide hypoglycemic drug BGM0504 injection is still in the research and development stage

Borui Pharmaceutical disclosed the stock trading risk warning announcement. The polypeptide hypoglycemic drug BGM0504 injection independently developed by the company's holding subsidiary Borui Xinchuang Biomedical Technology (Wuxi) Co., Ltd. is still in the research and development stage. Up to now, the two indications for weight loss and type 2 diabetes treatment have only obtained ethical approval documents for phase II clinical trials, among which phase II clinical trials for type 2 diabetes treatment have begun to enter the group. After the completion of the phase II clinical trial, it is necessary to confirm the confirmatory clinical trial scheme by the State Food and Drug Administration, carry out and complete the phase III clinical study, and be reviewed and approved by the State Food and Drug Administration before production and listing.

wanhua chemical: net profit of 12.703 billion yuan in the first three quarters decreased by 6.65 year on year

Wanhua Chemical disclosed its third-quarter report that the company achieved operating income of 132.554 billion yuan in the first three quarters, up 1.64 percent from the same period last year, net profit of 12.703 billion yuan, down 6.65 percent from the same period last year, and basic earnings per share of 4.05 yuan. In the first three quarters, the company extended the product industry chain, improved the regional layout, released the production capacity of new devices, and the sales volume of each major business segment increased year-on-year. Affected by the year-on-year decline in global crude oil, natural gas and other basic energy prices, the company's main chemical raw materials and European companies' energy costs fell year-on-year, but downstream demand is in the recovery stage, and product prices have declined year-on-year.

joy zhixing: Luo yinhao, one of the company's actual controllers, was lifted from compulsory measures

Joy Zhixing announced that Luo Yinhao, one of the company's actual controllers, recently received the "Decision to Revoke the Case" and the "Decision to Dismiss the Bail Pending Trial" issued by the Yinzhou Branch of the Ningbo Public Security Bureau. The Yinzhou Branch of the Ningbo Public Security Bureau decided to cancel the case and lift Luo Yinhao's bail pending trial measures because there was no crime.

Shenlian Biology: intends to cooperate in the development of vaccines to prevent both African swine fever and swine blue ear disease

shenlian biology (688098) announced that the company recently signed the "technology development (cooperation) contract for blue ear disease gene engineering live vector vaccine against African swine fever" with Shanghai veterinary research institute of Chinese academy of agricultural sciences. the two sides intend to jointly develop blue ear disease gene engineering live vector vaccine against African swine fever, which can prevent African swine fever and swine blue ear disease at the same time. At present, the vaccine has made good progress in the laboratory research stage, and important data have been accumulated in the safety and effectiveness of the vaccine. The project has passed the evaluation of "intermediate test" of transgenic safety of the Ministry of Agriculture and Rural Affairs.

Nangang shares: shagang group and others withdraw from the transaction involving the equity of Nanjing steel union, the controlling shareholder of the company

Nangang shares disclose the progress of the proposed change of the company's actual controller. The company's indirect controlling shareholder Shanghai Fosun High-Tech (Group) Co., Ltd. and its subsidiaries intend to sell 60% of the company's controlling shareholder Nanjing Ganglian. On October 13, the company received a letter of notification from Nangang Group. Nangang Group received a civil mediation letter made by the Jiangsu Provincial High Court on the same day. After mediation by the Jiangsu Provincial High People's Court, the parties voluntarily reached an agreement. Shagang Group, Shagang Investment voluntarily withdrew from the transaction involving 60% equity of Nanjing Steel Union, and Nangang Group paid compensation to Shagang Group and Shagang Investment. The parties through friendly consultations, efforts to achieve a win-win situation. At present, the company's production and operation is normal.

Baihua Medicine: The company has no production and sales of weight loss-related drugs

Baihua Pharmaceuticals has issued a stock price change announcement. Recently, some investors have paid more attention to the company's weight loss drugs and drugs suitable for senile dementia. The company's service mode is to accept the entrustment of customers and provide technical services related to pharmaceutical research and development, including the whole process technical services of generic CRO such as preclinical research, clinical research and registration. After the research and development is completed, the research and development results will be transferred to customers. The company has no related drug production and sales business.

Operating Results

Performance growth

yisheng shares: net profit in the first three quarters was 0.684 billion yuan, turning losses into profits year on year

Li Chen industrial: net profit in the first three quarters increased by 35.51-41.96 year on year

tianyi shangjia: net profit in the first three quarters increased by 85.65-101.8 year on year

Jinling hotel: net profit in the first three quarters increased by 82.42 year on year

huadian power international: net profit in the first three quarters increased by 75%-110 year on year

zhongxin tourism: pre-profit of 10 million -15 million yuan in the first three quarters, up from a year earlier

Shanghai Airport: Pudong Airport Passenger Throughput Grows 196.42 Percent YoY in September

Yanjin shop: net profit in the first three quarters increased by 78.7-83.28 year on year

faw liberation: pre-profit of 0.405 billion -0.43 billion yuan in the first three quarters, a year-on-year turnaround

Conmbe: net profit in the first three quarters increased by 150 to 200% year on year

changhong meiling: net profit in the first three quarters increased by 195.93-220.6 year on year

Performance decline

Zhangjiajie: expected net profit loss of 45 million -58 million yuan in the first three quarters

Xi' an tourism: net profit loss of 64.5346 million yuan in the first three quarters

Xichang electric power: it is expected to lose 32.54 million yuan in the first three quarters, with a year-on-year loss

textile city: net profit in the first three quarters decreased by 61.94-67.79 year on year

Increase and decrease holdings and repurchase

Reduce and promise not to reduce

China Nuclear Titanium Dioxide: The controlling shareholder voluntarily promised not to reduce the company's shares for 6 months

Shanghai Yizhong: Shareholder Sun Jing's plan to reduce his shareholding in the company has been completed, with a cumulative reduction of about 320000 shares

Repo

palm interest technology: to 50 million to 0.1 billion yuan to buy back shares for cancellation and reduction of registered capital

Important

Investment Cooperation

huaxin environmental protection: 0.8 billion yuan to invest in precious metals and non-ferrous metals extraction project

three trees: a paint production and supporting construction project to be built in 1.386 billion yuan

yike food: to invest in the whole industrial chain project of 100 million high-bay ducks in Guangdong, hong kong and Macao bay area (high-end)

Project Winning

high energy environment: jointly won the bid of 0.241 billion yuan soil remediation project

tianfu energy: the holding subsidiary recently won the total bid of 0.17 billion yuan project

hongrun construction: winning the bid for the supporting infrastructure construction project of logistics park of about 0.27 billion yuan

Other Matters

Lizhu Group: Approved for Clinical Trial of Iragol Sodium Tablets

Shanshan shares: repurchase of 15% equity of subsidiary completed in advance of delivery

Hanyi shares: subsidiaries and related parties to jointly acquire 100 of the shares of Aji network

China's jacaranda: proposed 100MW/400MWh gravity energy storage project and related industries

yuehongyuan a: the company and its subsidiaries have never developed and operated the "hongyuan huansheng" website and its APP

Risk Alert

hanbang high tech: the shares of Mr. Wang Liqun, a shareholder holding more than 5% of the shares, were frozen on the waiting list, accounting for 5.95 of the company's total share capital